Table 1.
Recent drugs, targets, and clinical trials in head and neck cancers.
| Class of drugs | Commercial name | Target | Head and neck clinical trials |
|---|---|---|---|
| E7080 | VEGFR2 | Phase II | |
| Erlotinib | Tarceva | EGFR | Phase III |
| Gefitinib | Iressa | EGFR | Phase II |
| Imatinib | Gleevac | PDGFR, BCR-ABL, KIT | Phase II |
| Lapatinib | Tykerb | EGFR | Phase III |
| Pazopanib | Votrient | VEGFR, PDGFR, KIT | Phase II |
| Sorafenib | Nexavar | VEGFR, PDGFR, KIT, FLT-3 RAF | Phase II |
| Sunitinib | Sutin | VEGFR, PDGFR, KIT, FLT-3 RET | Phase II |
| Vandetanib | Zactima | VEGFR, RET,EGFR | Phase II/III |
| XL-184 | MET, VEGFR, RET | Phase III | |
| Bexarotene | Targretin | RXR | Pilot study |
| Irofulven + capecitabine | MGI-114 + Xeloda | p53, MDR1 | Phase III |
| Bevacizumab | Avastin | VEGF | Phase III |
| Cetuximab | Erbitux | EGFR | Phase III |
| Nimotuzumab | BIOMAb EGFR | EGFR | Phase III |
| Panitumumab | Vetibix | EGFR | Phase II |
| Trastuzumab | Herceptin | ErbB2 | Phase II |
| Zalutumumab | HuMax-EGFr | EGFR | Phase III |
| Temsirolimus | Torisel | mTOR (PI3k) | Phase II |
| Bortezomib | Velcade | 26s Proteasome inhibitor | Phase II |
| Valproic | Acid epigenetic alterations | Phase II | |
| Oxaliplatin | Eloxatin | Induction of Bax/Bak | Phase II |
| Docetaxel | Taxotere | Microtubules | Phase III |
(NCI www.cancer.gov/clinicaltrials website).